Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omeprazole controlled release - AGI Therapeutics

Next Previous
Drug Profile

Omeprazole controlled release - AGI Therapeutics

Alternative Names: AGI-010; Chronab omeprazole

Latest Information Update: 06 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AGI Therapeutics
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Barrett's oesophagus; Gastro-oesophageal reflux

Most Recent Events

  • 08 Jun 2015 Discontinued - Phase-II for Gastro-oesophageal reflux in Canada (PO)
  • 14 Aug 2009 Axcan Pharma terminates its licence for AGI Therapeutics' controlled-release omeprazole in North America
  • 14 Aug 2009 Controlled-release omeprazole is available for licensing (http://www.agitherapeutics.com)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top